NO and angiogenesis

被引：220

作者：

Cooke, JP ^{[1
]}

机构：

[1] Stanford Univ, Sch Med, Program Vasc Med & Biol, Stanford, CA 94305 USA

来源：

ATHEROSCLEROSIS SUPPLEMENTS | 2003年 / 4卷 / 04期

关键词：

angiogenesis; asymmetric dimethylarginine; HMG coA reductase inhibition; L-arginine; NOS;

D O I：

10.1016/S1567-5688(03)00034-5

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Angiogenesis requires the elaboration of endothelium-derived nitric oxide (NO). Angiogenic factors induce the release of NO from endothelial cells, which mediates a multiplicity of processes involved in angiogenesis. These NO-modulated processes include endothelial cell survival, proliferation, migration, and interaction with the extracellular matrix. Derangements of the NO synthase pathway impair angiogenesis. Accordingly, the competitive inhibitor of the NOS pathway asymmetric dimethylarginine (ADMA) acts as an endogenous inhibitor of angiogenesis. By contrast, agents which increase NO synthesis, such as low dose statins, enhance angiogenesis. Modulation of the NO synthase pathway could become a new therapeutic avenue for angiogenesis-related disorders. (C) 2003 Elsevier Ireland Ltd. All rights reserved.

引用

页码：53 / 60

页数：8

共 80 条

[1] Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus [J].

Abbasi, F ;

Asagmi, T ;

Cooke, JP ;

Lamendola, C ;

McLaughlin, T ;

Reaven, GM ;

Stuehlinger, M ;

Tsao, PS .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (10) :1201-+

[2] Bacterial toxins block endothelial wound repair - Evidence that Rho GTPases control cytoskeletal rearrangements in migrating endothelial cells [J].

Aepfelbacher, M ;

Essler, M ;

Huber, E ;

Sugai, M ;

Weber, SC .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (09) :1623-1629

[3]

ASAGMI T, 2002, METABOLISM, V51

[4] Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor [J].

Babaei, S ;

Teichert-Kuliszewska, K ;

Monge, JC ;

Mohamed, F ;

Bendeck, MP ;

Stewart, DJ .

CIRCULATION RESEARCH, 1998, 82 (09) :1007-1015

[5]

Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424

[6] 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer -: A nested case-control study [J].

Blais, L ;

Desgagné, A ;

LeLorier, J .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2363-2368

[7] Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits [J].

BodeBoger, SM ;

Boger, RH ;

Kienke, S ;

Junker, W ;

Frolich, JC .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 219 (02) :598-603

[8] Asymmetric dimethylarginine (ADMA):: A novel risk factor for endothelial dysfunction -: Its role in hypercholesterolemia [J].

Böger, RH ;

Bode-Böger, SM ;

Szuba, A ;

Tsao, PS ;

Chan, JR ;

Tangphao, O ;

Blaschke, TF ;

Cooke, JP .

CIRCULATION, 1998, 98 (18) :1842-1847

[9] Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins [J].

Brouet, A ;

Sonveaux, P ;

Dessy, C ;

Moniotte, S ;

Balligand, JL ;

Feron, O .

CIRCULATION RESEARCH, 2001, 89 (10) :866-873

[10] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

← 1 2 3 4 5 6 7 8 →